Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1061-1069

  Yamamoto, Noboru ^a   Tamura, Tomohide ^a   Murakami, Haruyasu ^a   Shimoyama, Tatsu ^a   Nokihara, Hiroshi ^a   Ueda, Yutaka ^a   Sekine, Ikuo ^a   Kunitoh, Hideo ^a   Ohe, Yuichiro ^a   Kodama, Tetsuro ^a   Shimizu, Mikiko ^a   Nishio, Kazuto ^a   Ishizuka, Naoki ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DOCETAXEL; HYDROCORTISONE; 6 BETA-HYDROXYCORTISOL; 6BETA HYDROXYHYDROCORTISONE; ANTINEOPLASTIC AGENT; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; DRUG DERIVATIVE; TAXOID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; LUNG TUMOR; METABOLISM; MIDDLE AGED; URINE;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BODY SURFACE AREA; CARCINOMA, NON-SMALL-CELL LUNG; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROCORTISONE; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 20044369878     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.036     Document Type: Article

References (43)

1. Sawyer M, Ratain MJ: Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177, 2001
2. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
3. Ratain MJ: Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? J Clin Oncol 16:2297-2298, 1998
4. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291, 1991
5. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
6. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
7. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
8. Gandara DR, Vokes E, Green M, et al: Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol 18:131-135, 2000
9. Kunitoh H, Watanabe K, Onoshi T, et al: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study. J Clin Oncol 14:1649-1655, 1996
10. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
11. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
12. Hudis CA, Seidman AD, Crown JP, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
13. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428, 1996
14. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: The 303 Study Group. J Clin Oncol 17:2341-2354, 1999
15. Marre F, Sanderink GJ, de Sousa G, et al: Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302, 1996
16. Nelson DR, Koymans L, Kamataki T, et al: P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42, 1996
17. Lin JH, Lu AYH: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390, 1998
18. Parkinson A: An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:45-57, 1996
19. Shimada T, Yamazaki H, Mimura M, et al: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423, 1994
20. Guengerich FP: Characterization of human microsomal cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 29:241-264, 1989
21. Guengerich FP, Turvy CG: Comparison of levels of human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease status using immunochemical analysis of surgical samples. J Pharmacol Exp Ther 256:1189-1194, 1991
22. Hunt CM, Westerkam WR, Stave GM: Effects of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275-283, 1992
23. Watkins PB, Turgeon DK, Saenger P, et al: Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 52:265-273, 1992
24. Kinirons MT, O'Shea D, Downing TE, et al: Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54:621-629, 1993
25. Hunt CM, Watkins PB, Saenger P, et al: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51:18-23, 1992
26. Thummel KE, Shen DD, Podoll TD, et al: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intra-individual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557-566, 1994
27. Thummel KE, Shen DD, Podoll TD, et al: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549-556, 1994
28. Hirth J, Watkins PB, Strawderman M, et al: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258, 2000
29. Goh BC, Lee SC, Wang LZ, et al: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690, 2002
30. Yamamoto N, Tamura T, Kamiya Y, et al: Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18:2301-2308, 2000
31. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
32. Nakamura J, Yakata M: Determination of urinary cortisol and 6 beta-hydroxycortisol by high performance liquid chromatography. Clin Chim Acta 149:215-224, 1985
33. Lykkesfeldt J, Loft S, Poulsen HE: Simultaneous determination of urinary free cortisol and 6 beta-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Appl 660:23-29, 1994
34. Vergniol JC, Bruno R, Montay G, et al: Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278, 1992
35. Taguchi T, Furue H, Niitani H, et al: Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho 21:1997-2005, 1994
36. Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11:950-958, 1993
37. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
38. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84:1781-1788, 1992
39. Mathijssen RHJ, Verweij J, de Jonge MJ, et al: Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 20:81-87, 2002
40. De Jongh FE, Verweij J, Loos WJ, et al: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733-3739, 2001
41. Gurney HP, Ackland S, Gebski V, et al: Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299-2304, 1998
42. Loos WJ, Gelderblom H, Sparreboom A, et al: Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens. Clin Cancer Res 6:2685-2689, 2000
43. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998